Foresee Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI ETM (leuprolide mesylate 21 mg, ready-to-use long-acting injectable (LAI) formulation administered every 3 months), as a treatment for advanced prostate cancer. The FDA approval was based on the Phase 3 clinical study with 144 advanced prostate cancer patients enrolled. Treatment with CAMCEVI ETM was effective, safe, and well-tolerated, with 97.9% of the s...